Corvus Pharmaceuticals's total assets for Q2 2024 were $64.56M, an increase of 61.06% from the previous quarter. CRVS total liabilities were $6.22M for the fiscal quarter, a -7.49% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.